Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant concerns: a net loss of $54.7 million, limited cash reserves, and ongoing economic and financial risks. The Q&A section highlights unproven commercial execution strategies and unclear timelines for manufacturing and regulatory approvals. While there is optimism for future product launches, the lack of finalized pricing strategies and potential supply chain issues further contribute to a negative outlook. These factors outweigh any positive aspects, suggesting a likely stock price decline in the short term.
Key Financial Performance
Cash, Cash Equivalents, and Marketable Securities $36.4 million as of December 31, 2025.
Total Operating Expenses (Q4 2025) $14.7 million, reflecting ongoing investment in regulatory, clinical, pre-commercial, and commercial infrastructure activities.
Total Operating Expenses (Full Year 2025) $54.9 million, reflecting ongoing investment in regulatory, clinical, pre-commercial, and commercial infrastructure activities.
Net Loss (Q4 2025) $14.7 million.
Net Loss (Full Year 2025) $54.7 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Cytisinicline NDA Submission: Achieve Life Sciences submitted a New Drug Application (NDA) for cytisinicline for smoking cessation, which was accepted by the FDA. This marks a significant step towards becoming the first FDA-approved treatment for smoking cessation in 20 years.
Vaping Cessation Indication: Cytisinicline received the FDA Commissioner's National Priority Voucher for vaping cessation, providing an expedited review timeline and positioning it as the first FDA-approved treatment for e-cigarette cessation.
Clinical Data and Safety: The ORCA-OL long-term exposure trial demonstrated cytisinicline's safety and tolerability over a 52-week period, with strong patient satisfaction. Additionally, data published in Thorax showed improved smoking quit rates in COPD patients.
Market Opportunity: Targeting 25 million smokers and 18 million e-cigarette users in the U.S., with a focus on addressing nicotine dependence as a medical condition.
Commercial Infrastructure: Achieve has built a scalable, AI-powered commercial model to target high-volume prescribers and motivated patients efficiently.
Manufacturing Partnership: Achieve partnered with Adare Pharma Solutions to establish U.S.-based manufacturing for cytisinicline, ensuring supply chain security and reducing risks associated with international imports.
Digital Commercial Platform: The company developed an AI-powered platform for precision targeting, customer engagement, and predictive insights to enhance operational efficiency.
Awareness Campaign: Launched the 'Will Power' campaign to reframe nicotine dependence as a medical condition requiring treatment, challenging outdated narratives.
Regulatory and Clinical Advancements: Achieve is advancing through the FDA review process and preparing for the ORCA-V2 Phase III trial for vaping cessation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The manufacturer named in the cytisinicline NDA recently had an FDA Good Manufacturing Practices inspection with two observations related to solid oral dose manufacture. These issues are being addressed, but they pose a potential risk to the approval process and supply chain reliability.
Supply Chain Risks: Reliance on international pharmaceutical importation poses risks such as tariffs and uncertainties. While the partnership with Adare Pharma Solutions aims to mitigate these risks, the transition and technology transfer process could introduce delays or challenges.
Market Access and Pricing Risks: Securing rapid, broad, and affordable coverage for cytisinicline remains a challenge. Discussions with payers are ongoing, and feedback will be critical in finalizing pricing and access strategies, which could impact market penetration and revenue.
Commercial Execution Risks: The company is building a new AI-powered, data-driven commercial infrastructure. While this approach is innovative, its effectiveness in achieving scalable and efficient market penetration remains unproven.
Economic and Financial Risks: The company reported a net loss of $54.7 million for 2025 and continues to evaluate financing options. Limited cash reserves could impact the ability to sustain operations and execute strategic objectives if additional funding is not secured.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
NDA Approval and Commercial Launch: Achieve Life Sciences aims to receive NDA approval and launch cytisinicline for smoking cessation in the first half of 2027. The company is preparing for a controlled and successful launch, including securing supply chain readiness through a partnership with Adare Pharma Solutions.
Vaping Cessation Indication: Achieve plans to leverage the FDA Commissioner's National Priority Voucher to expedite the NDA review process for cytisinicline as a vaping cessation treatment. The company is preparing for the ORCA-V2 Phase III trial for vaping cessation.
Market Opportunity and Growth: The company is targeting a significant market opportunity, with 25 million smokers and 18 million e-cigarette users in the U.S., many of whom are seeking to quit. Achieve aims to position cytisinicline as the first FDA-approved treatment for vaping cessation and the first new smoking cessation treatment in 20 years.
Digital Commercial Platform: Achieve is building an AI-powered, data-driven commercial platform to enhance decision-making, automate customer engagement, and optimize resource allocation. This platform will support precision targeting of physicians and patients, enabling efficient scaling and measurable impact.
Regulatory and Clinical Progress: The company is advancing through the FDA review process for cytisinicline and has presented positive clinical data, including long-term safety and efficacy results. Achieve is confident in cytisinicline's potential to address nicotine dependence across diverse patient populations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the critical path between a late June NDA approval and the first-half 2027 launch?
A:The critical path involves ensuring drug availability in the supply chain, readiness of trade and distribution processes, and operational preparations such as partnerships with advocacy groups and policymakers. The additional time allows for gathering more data and optimizing the product launch.
Q:Will the manufacturer in the NDA supply the commercial product, or will Adare take over?
A:The manufacturer in the NDA will not supply the commercial product. Adare will take over manufacturing due to geopolitical considerations and the need for contingency supply. The PDUFA date remains June 20, 2026.
Q:What is the current awareness among healthcare providers (HCPs) about cytisinicline, and what are the plans to build awareness?
A:HCP awareness has not been a priority due to regulatory restrictions in the pre-approval phase. Efforts have focused on disease state education. Awareness campaigns will ramp up closer to the launch, with presentations at conferences like ATS to disseminate new data.
Q:What is the status of FDA dialogue on the vaping indication?
A:Discussions with the FDA have focused on protocol approval. Site selection is underway, and the study is expected to commence in the first half of the year. The company sees a significant opportunity as the first-in-market for a vaping-cessation product.
Q:Does the U.S. commercial launch timeline of 1H 2027 assume a June 2026 approval?
A:Yes, the timeline assumes a June 2026 approval. The first-half 2027 launch is planned to ensure all commercial and manufacturing activities are completed. Adare will be added to the NDA post-approval.
Q:What can be expected regarding insurance coverage at launch?
A:Insurance coverage is expected to align with normal launches, aided by the Affordable Care Act's requirement for smoking-cessation treatment coverage. Conversations with payers are ongoing, and initial restrictions like new-to-market blocks will require a ramp period post-launch.
Q:Can third-party suppliers meet demand if Sopharma is unable to supply raw plant material?
A:Yes, the company has been stockpiling raw plant material and expects to have more than three years of supply by launch. The inventory will be maintained at this level for the foreseeable future.
Q:Is there concern about the cytisinicline dosing schedule limiting compliance or uptake?
A:No, the three-times-a-day dosing schedule has not been found burdensome. High adherence rates were observed in trials, with participants finding the schedule helpful in managing cravings around mealtimes.
Q:How does the ICER report on cytisinicline pricing compare with internal calculations?
A:The company has seen the ICER report, which highlights the unmet need and recommends immediate availability of cytisinicline. However, the company has not finalized or disclosed its pricing strategy.
Q:What is the status of manufacturing with Sopharma, Adare, and the European manufacturer?
A:Sopharma was excluded from the NDA due to inspection-readiness concerns but may be added post-approval. Observations with the European manufacturer are being addressed. Adare is expected to be added to the NDA in Q3, with manufacturing moved to the U.S. for contingency and redundancy.
Q:Review of Unclear Management Responses
A:Management avoided providing specific pricing details for cytisinicline, stating that pricing discussions with payers have not yet occurred. Additionally, there was some lack of clarity around the observations with the European manufacturer and the exact timeline for their resolution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adare
Commissioner National
Dr Rubinstein
FDA treatment
III trial
National Priority
Nicotine
ORCA OL
Oki
Phase III
Priority Voucher
Society
adult
analytics
attempt
beginning
campaign
cigarette cessation
cost
customer engagement
cytisinicline patient
cytisinicline term
decision
drug product
health care
infrastructure
peer
people treatment
plan
position
prescribers
priority availability
progress cytisinicline
society
summary
supply chain
technology
transformation
ACHV Transcript
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals significant concerns: a net loss of $54.7 million, limited cash reserves, and ongoing economic and financial risks. The Q&A section highlights unproven commercial execution strategies and unclear timelines for manufacturing and regulatory approvals. While there is optimism for future product launches, the lack of finalized pricing strategies and potential supply chain issues further contribute to a negative outlook. These factors outweigh any positive aspects, suggesting a likely stock price decline in the short term.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed outlook. The company is on track with NDA submission and has positive clinical trial results, but faces financial challenges with a significant cash burn and net loss. The Q&A section reveals cautious optimism about pricing strategy and partnerships, but lacks clarity in some areas. The focus on cash management and the absence of priority review expectations temper the outlook. Overall, the sentiment is neutral, reflecting both potential positives and ongoing uncertainties.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call summary shows a mixed outlook. Financial performance is weak with ongoing losses and limited cash runway, but there's a slight EPS beat. Product development is progressing with NDA submission and breakthrough therapy designation. However, commercial launch is years away. Market strategy focuses on awareness and partnerships, but lacks immediate catalysts. Risks include regulatory hurdles and competition. Shareholder returns are not addressed. Q&A reveals cautious optimism, but management's vague responses on commercialization timing and partnerships add uncertainty. Overall, the sentiment is neutral, with no strong positive or negative catalysts in the short term.
ACHV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
